UniQure is making ready to hunt accelerated FDA approval for its Huntington’s illness gene remedy, a transfer that follows the FDA’s reversal of its prior place calling for one more medical trial. This gene remedy is the newest in a rising record of uncommon illness remedies to obtain reconsideration from an FDA that seems to be swinging again to regulatory flexibility.
The submit FDA Reversal on uniQure Gene Remedy Is One other Signal of Renewed Regulatory Flexibility appeared first on MedCity Information.
